Results 21 to 30 of about 218,870 (301)

Doxorubicin Cardiomyopathy [PDF]

Cardiology, 2009
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained.
Kanu, Chatterjee, Jianqing, Zhang, Norman, Honbo, Joel S, Karliner   +3 more
openaire   +2 more sources

Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT [PDF]

, 2017
Background: Preclinical studies have reported that a single treadmill session performed 24 h prior to doxorubicin provides cardio-protection. We aimed to characterize the acute change in cardiac function following an initial doxorubicin treatment in ...
Shave, R. E., Gelmon, Karen, Kirkham, Amy, Stöhr, E. J., Stöhr, Eric J., K.L. Campbell, D.E.R. Warburton, N.D. Eves, A.A. Kirkham, K.A. Gelmon, Bland, K. A., Bovard, Josh, K.A. Bland, Warburton, Darren E. R., Virani, Sean, E.J. Stöhr, Virani, S. A., Gelmon, Karen, 1953-, Eves, N. D., Bland, Kelcey, S.A. Virani, McKenzie, Don (Donald Chisholm), Bovard, J. M., Kirkham, Amy Ashley, J.M. Bovard, Shave, Rob, D.C. McKenzie, Campbell, Kristin, Campbell, K. L., Eves, Neil, Warburton, Darren, R.E. Shave   +31 more
core   +1 more source

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

BMC Cancer, 2008
Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei, Xu Qiong, Liang Yu, Jia Jing, Lu Rong, Chen Li-juan, Zhu Zhi-feng, Wang Li, Wang Song, Yao Zhi   +9 more
doaj   +1 more source

Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Cardio-Oncology, 2020
Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li, Hui-Ming Chang, Jose Banchs, Dejka M. Araujo, Saamir A. Hassan, Elizabeth A. Wagar, Edward T. H. Yeh, Qing H. Meng   +7 more
doaj   +1 more source

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials [PDF]

, 2010
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.Methods: Randomized controlled ...
Gill Levitt, Smith Lesley A, Cornelius Victoria R, Canney Peter, Levitt, G, Smith, Lesley A., Canney, P, Verrill, Mark, Lesley A Smith, Cornelius, Victoria, Verrill Mark, Plummer, CJ, Verrill, M, Peter Canney, Cornelius, VR, Lesley, A. Smith, Canney, Peter, Plummer, Christopher J., Victoria R Cornelius, Plummer Christopher J, Alison Jones, Smith, LA, Christopher J Plummer, Jones, Alison, Jones Alison, Jones, A, Levitt Gill, Levitt, Gill, Cornelius, Victoria R., Mark Verrill   +29 more
core   +1 more source

Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells

Cancer Cell International, 2018
Background Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters.
Shao-hsuan Wen, Shey-chiang Su, Bo-huang Liou, Cheng-hao Lin, Kuan-rong Lee   +4 more
doaj   +1 more source

Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice

Pharmaceuticals, 2023
Sex is a salient risk factor in the development of doxorubicin-induced cardiotoxicity. Sex differences in the heart’s ability to respond to hypertrophic stimuli in doxorubicin-exposed animals have not been reported.
Kevin Agostinucci, Marianne K. O. Grant, Wongel Melaku, Chandini Nair, Beshay N. Zordoky   +4 more
doaj   +1 more source

Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients

BMC Veterinary Research, 2021
Background Both human and veterinary cancer chemotherapy are undergoing a paradigm shift from a “one size fits all” approach to more personalized, patient-oriented treatment strategies.
Kristine Walters, Alessia Stornetta, Foster Jacobs, Peter W. Villalta, Maria Razzoli, Marianne Grant, Beshay Zordoky, Alessandro Bartolomucci, Antonella Borgatti, Silvia Balbo   +9 more
doaj   +1 more source

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]

PLoS ONE, 2015
Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard, Andrea Pavia-Jimenez, Weina Chen, Noelle S Williams, Harris Naina, Robert Collins, James Brugarolas, Jin Ye   +7 more
doaj   +1 more source

Doxorubicin

Reactions Weekly
Johnson-Arbor K, Douedi S, Patel P.
europepmc   +5 more sources